547 related articles for article (PubMed ID: 23071358)
1. IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives.
Yang H; Ye D; Guan KL; Xiong Y
Clin Cancer Res; 2012 Oct; 18(20):5562-71. PubMed ID: 23071358
[TBL] [Abstract][Full Text] [Related]
2. Targeting isocitrate dehydrogenase (IDH) in cancer.
Fujii T; Khawaja MR; DiNardo CD; Atkins JT; Janku F
Discov Med; 2016 May; 21(117):373-80. PubMed ID: 27355333
[TBL] [Abstract][Full Text] [Related]
3. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.
Xu W; Yang H; Liu Y; Yang Y; Wang P; Kim SH; Ito S; Yang C; Wang P; Xiao MT; Liu LX; Jiang WQ; Liu J; Zhang JY; Wang B; Frye S; Zhang Y; Xu YH; Lei QY; Guan KL; Zhao SM; Xiong Y
Cancer Cell; 2011 Jan; 19(1):17-30. PubMed ID: 21251613
[TBL] [Abstract][Full Text] [Related]
4. D-2-Hydroxyglutarate in Glioma Biology.
Chou FJ; Liu Y; Lang F; Yang C
Cells; 2021 Sep; 10(9):. PubMed ID: 34571995
[TBL] [Abstract][Full Text] [Related]
5. IDH1 mutations inhibit multiple α-ketoglutarate-dependent dioxygenase activities in astroglioma.
Liu Y; Jiang W; Liu J; Zhao S; Xiong J; Mao Y; Wang Y
J Neurooncol; 2012 Sep; 109(2):253-60. PubMed ID: 22772731
[TBL] [Abstract][Full Text] [Related]
6. Registered report: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
Fiehn O; Showalter MR; Schaner-Tooley CE; ;
Elife; 2016 Feb; 5():. PubMed ID: 26943899
[TBL] [Abstract][Full Text] [Related]
7. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.
Gross S; Cairns RA; Minden MD; Driggers EM; Bittinger MA; Jang HG; Sasaki M; Jin S; Schenkein DP; Su SM; Dang L; Fantin VR; Mak TW
J Exp Med; 2010 Feb; 207(2):339-44. PubMed ID: 20142433
[TBL] [Abstract][Full Text] [Related]
8. Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates.
Ye D; Guan KL; Xiong Y
Trends Cancer; 2018 Feb; 4(2):151-165. PubMed ID: 29458964
[TBL] [Abstract][Full Text] [Related]
9. Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis.
Ohba S; Hirose Y
Neurol Med Chir (Tokyo); 2016; 56(4):170-9. PubMed ID: 26960449
[TBL] [Abstract][Full Text] [Related]
10. Isocitrate dehydrogenase gene mutations and 2-hydroxyglutarate accumulation in esophageal squamous cell carcinoma.
Miyake K; Baba Y; Ishimoto T; Hiyoshi Y; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Ogata Y; Nagayama M; Silsirivanit A; Kobayashi D; Araki N; Baba H
Med Oncol; 2018 Nov; 36(1):11. PubMed ID: 30506321
[TBL] [Abstract][Full Text] [Related]
11. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S; Yim S; Park H
Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
[TBL] [Abstract][Full Text] [Related]
12. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
Ward PS; Patel J; Wise DR; Abdel-Wahab O; Bennett BD; Coller HA; Cross JR; Fantin VR; Hedvat CV; Perl AE; Rabinowitz JD; Carroll M; Su SM; Sharp KA; Levine RL; Thompson CB
Cancer Cell; 2010 Mar; 17(3):225-34. PubMed ID: 20171147
[TBL] [Abstract][Full Text] [Related]
13. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.
Jin G; Reitman ZJ; Spasojevic I; Batinic-Haberle I; Yang J; Schmidt-Kittler O; Bigner DD; Yan H
PLoS One; 2011 Feb; 6(2):e16812. PubMed ID: 21326614
[TBL] [Abstract][Full Text] [Related]
14. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer.
Losman JA; Kaelin WG
Genes Dev; 2013 Apr; 27(8):836-52. PubMed ID: 23630074
[TBL] [Abstract][Full Text] [Related]
15. Replication Study: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
Showalter MR; Hatakeyama J; Cajka T; VanderVorst K; Carraway KL; Fiehn O;
Elife; 2017 Jun; 6():. PubMed ID: 28653623
[TBL] [Abstract][Full Text] [Related]
16. Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.
Kato Y
Brain Tumor Pathol; 2015 Jan; 32(1):3-11. PubMed ID: 25324168
[TBL] [Abstract][Full Text] [Related]
17. Role of isocitrate dehydrogenase 1/2 (IDH 1/2) gene mutations in human tumors.
Liu X; Ling ZQ
Histol Histopathol; 2015 Oct; 30(10):1155-60. PubMed ID: 26147657
[TBL] [Abstract][Full Text] [Related]
18. Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2.
Borodovsky A; Seltzer MJ; Riggins GJ
Curr Opin Oncol; 2012 Jan; 24(1):83-9. PubMed ID: 22080945
[TBL] [Abstract][Full Text] [Related]
19. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization.
Ward PS; Lu C; Cross JR; Abdel-Wahab O; Levine RL; Schwartz GK; Thompson CB
J Biol Chem; 2013 Feb; 288(6):3804-15. PubMed ID: 23264629
[TBL] [Abstract][Full Text] [Related]
20. Isocitrate dehydrogenase variants in cancer - Cellular consequences and therapeutic opportunities.
Liu S; Cadoux-Hudson T; Schofield CJ
Curr Opin Chem Biol; 2020 Aug; 57():122-134. PubMed ID: 32777735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]